Novo's Silent 4,000: The Non-Denmark Resume Pivot to Lilly and Roche

On Sept 21, 2026, CEO Mike Doustdar told Novo Nordisk's Capital Markets Day audience in London that headcount has already fallen by 13,000 in a year, 4,000 more than the 9,000 announced in September 2025. Denmark alone dropped from 33,820 to 26,511 between Sept 2025 and July 2026, which means roughly 5,700 of the cuts landed outside Denmark, mostly in HR, clinical development, regulatory, legal, marketing, finance, and rare-disease functions. If you were one of them, the resume you filed at Bagsværd is not the resume that gets you into Lilly, Roche, or Structure.

The real number is 13,000, and 5,700 of them are not Danish

Novo has cut 13,000 roles worldwide since Sept 2025, roughly 44% of them outside Denmark, and English-language coverage is still quoting the stale 9,000 figure. That gap matters for your resume, because recruiters at GLP-1 competitors are reading the same outdated headlines you are.

Here is what actually happened, pulled from Doustdar's Capital Markets Day disclosures and the Børsen numbers Ritzau reported:

The Sept 2025 announcement said "about 5,000" of the 9,000 would be Danish. The July 2026 Danish number tells you that piece landed and then some. What nobody has broken out is the international remainder, and that is where the resume rewrite work lives.

Why ex-Novo obesity leaders are structurally scarce, not oversupplied

Ex-Novo clinical development leaders working in obesity and cardiometabolic disease are among the scarcest talent in biopharma, not the most saturated, and your resume should say so on the first line. In Refolk's index of professional profiles across the US, UK, Switzerland, Denmark, and Germany, only 11 senior-to-VP-level "obesity/metabolic clinical development" leaders exist across all five countries combined. The named employers are AbbVie (2), Boehringer Ingelheim, Regeneron, Genentech, Neumora, and Novo Nordisk itself.

That is the entire senior bench, on both sides of the Atlantic, for the drug class projected to hit $180 billion by 2034.

The mechanism is simple. Semaglutide's clinical program ran inside Novo for a decade, and anyone with real Phase 3 GLP-1 leadership experience trained at Novo or Lilly. Roche only entered the category by paying $2.7 billion for Carmot. Structure Therapeutics initiated its Phase 3 ACCOMPLISH program for oral aleniglipron in Q2 2026. Amgen's MariTide is still reading out. None of these companies have a bench. They have one or two hires and a wishlist.

If you led any part of a semaglutide or cagrilintide program at Novo, your resume should not read "clinical development lead, obesity portfolio." It should read "one of eleven." State the program, the phase, the endpoints, the patient count, and the regulatory bodies. That is the specificity Roche's talent team in Basel is scanning for, and it is the exact work Refolk will do for you: paste the Roche or Structure posting, get your own resume back rewritten against it, with your Novo history reframed as portable cardiometabolic platform experience rather than employer-specific tenure.

Who is actually hiring, by function

The five real destinations for ex-Novo staff outside Denmark are Eli Lilly, Roche/Genentech (via Carmot), Structure Therapeutics, Zealand Pharma, and Amgen, with AstraZeneca and Pfizer as tier-two options. Each takes a different resume framing depending on your function.

• Clinical development, biostats, regulatory: Structure Therapeutics is staffing ACCOMPLISH (South San Francisco). Roche/Carmot is scaling CT-388 after 22.5% placebo-adjusted weight reduction at 48 weeks in Phase 2 (Basel and South SF). Zealand needs regulatory depth around petrelintide, its amylin drug partnered with Roche.
• Commercial and marketing: Lilly's Zepbound and oral Foundayo teams in Indianapolis are the default. Structure just appointed John Berrios as CCO citing his GLP-1 leadership, which signals commercial hiring underneath him.
• HR, legal, finance: These are the least transferable functions inside a niche competitor, so the pivot is broader pharma. Sanofi, GSK, and Takeda hire generalists faster than a Structure or a Carmot will.
• Rare disease: Novo's rare-disease franchise is not a GLP-1 story, so the pivot is Sanofi, Alnylam, Vertex, Ultragenyx, and BioMarin, not the obesity competitors.
• CMC, aseptic peptide manufacturing: Denmark-based Kalundborg staff should be reading Lonza, Catalent, Samsung Biologics, and Roche's Basel manufacturing openings.

Refolk's index shows 6,230 professionals with "Novo Nordisk" in their profile across the US, UK, Germany, Switzerland, and France, concentrated in Greater Boston, New York, and Zurich. Those are the geographic centers where ex-Novo talent already clusters, and where recruiters at Lilly, Roche, Structure, and Zealand's Boston office are already sourcing.

The 2032 patent cliff objection, and how your resume answers it

The single objection you will hear from every recruiter is that semaglutide goes off-patent in 2032 and the GLP-1 category is peaking, so your resume needs to pre-empt it in the summary line. Investors read Doustdar's Sept 21 CAGR guidance as an admission that the category is maturing, and CNBC noted it landed broadly in line with peers, disappointing the market. Add 1,722 GLP-1R-related patents filed since 2020 and a Chinese generic wave from Sinopep-Allsino, Qilu, CSPC Zhongqi, Hybio, and Zhejiang Apeloa Kangyu, and hiring managers are actively worried.

The counter is the 2027-2032 launch wave. Morningstar projects the GLP-1 drug market at $180 billion in 2034, with Pfizer, Roche, Amgen, AstraZeneca, Zealand, and Structure launches expected between 2027 and 2032. Every one of those launches needs Phase 3 leadership, US and EU regulatory strategy, and commercial scale-up. Your resume should name the drug class transitions your work touched: oral GLP-1s (Foundayo, aleniglipron), amylin (petrelintide, cagrilintide), and oral small molecules. Recruiters treat category fluency as evidence you can lead a next-generation program, not just retrospectively defend semaglutide.

Frame the pivot window explicitly. A line like "led Phase 3 execution on a GLP-1 program with 2029 filing window" tells a Structure or Amgen hiring manager you understand where their pipeline sits.

The Doustdar redirect: why HR, legal, and marketing pivots are hardest

Doustdar said explicitly that Novo's savings are being redirected into R&D and competitiveness, which is corporate speak for "the cuts came from support functions." That is why HR, legal, marketing, finance, and rare-disease commercial staff make up a disproportionate share of the non-Denmark 5,700. Those functions are also the least directly transferable inside a lean biotech.

The resume rewrite for these functions is different from the clinical one:

1. Stop leading with "pharma HR" or "life sciences legal." Those are shrinking categories inside biotech. Lead with the specific capability (executive comp for a public-company reorg, EU MDR readiness, DTC campaign management) and let the industry follow.
2. Reframe Novo's consumer-goods pivot as a credential. Doustdar has publicly said Novo will sell products more like consumer goods than traditional medicines. If you worked on Wegovy DTC, that is now the most transferable line on your resume.
3. Quantify against Novo's own strategy pivot. "Ran DTC acquisition for a $6B franchise" reads differently from "senior brand manager, obesity."
4. Target the pharma generalists, not the GLP-1 competitors. Sanofi, GSK, and Takeda are hiring support-function talent at a rate the pure-play GLP-1 competitors are not.

This is where a resume tailored per posting matters most, because the same Novo marketing history reads as consumer-health experience to one employer, DTC pharma experience to Lilly, and category launch experience to Structure. Refolk scores how well your history actually fits each posting before you send.

Denmark vs. international: two different talent pools

Ex-Novo talent inside Denmark is a fundamentally different candidate pool from the international 6,230, and the target employer lists should not overlap. Refolk's Denmark-only index surfaces just 87 Novo Nordisk profiles, and they skew heavily to CMC, aseptic peptide, and API manufacturing titles concentrated in Kalundborg and Copenhagen. The international pool skews clinical, commercial, and rare disease.

That means:

• Kalundborg CMC engineers should target Lonza, Catalent, Samsung Biologics, and Roche's Basel manufacturing site. Peptide synthesis and aseptic fill-finish scale are the resume keywords.
• Bagsværd clinical and commercial staff should target Zealand Pharma directly (Copenhagen and Boston), and treat Lilly, Roche, and Structure as the international pivots.
• Boston, Zurich, and NYC-based Novo staff are already sitting in the right geography. The rewrite work is functional framing, not relocation.

FAQ

How many Novo Nordisk employees were laid off in 2026?

Novo Nordisk has cut 13,000 full-time roles since September 2025, CEO Mike Doustdar disclosed at the Sept 21, 2026 Capital Markets Day. That is 4,000 more than the 9,000 originally announced. Denmark accounted for roughly 7,309 of those, dropping from 33,820 to 26,511 between Sept 2025 and July 2026. The implied non-Denmark cut is around 5,700, hitting HR, clinical development, regulatory, legal, marketing, finance, and rare-disease functions hardest.

Which companies are the best GLP-1 competitor targets for ex-Novo staff?

Eli Lilly (Indianapolis), Roche/Carmot (Basel and South San Francisco), Structure Therapeutics (South SF), Zealand Pharma (Copenhagen and Boston), and Amgen are the direct competitors actively hiring in obesity and cardiometabolic disease. Roche is spending publicly to become a "top three player" per CEO Teresa Graham, and Structure just initiated Phase 3 ACCOMPLISH for oral aleniglipron. AstraZeneca and Pfizer are tier-two options with 2027-2032 launch timelines.

How should ex-Novo marketing and HR staff reframe their resumes?

Support-function staff should reframe Novo experience around Doustdar's own stated consumer-goods pivot, since the GLP-1 competitors are hiring clinical and regulatory talent faster than commercial or HR. Wegovy DTC work reads as consumer-health experience to one buyer and launch experience to another. Target broader pharma (Sanofi, GSK, Takeda) for pure support roles, and lead with the specific capability rather than the industry label.

Does the 2032 semaglutide patent cliff hurt my resume?

Only if you let it define your experience. The GLP-1 market is projected at $180 billion in 2034 per Morningstar, with a wave of competitor launches from Pfizer, Roche, Amgen, AstraZeneca, Zealand, and Structure between 2027 and 2032. Frame your Novo work as portable to next-generation classes (oral GLP-1s, amylin, triple agonists) and name the filing windows your programs targeted, so recruiters read you as a next-launch leader rather than a semaglutide defender.